Company: IMRX
Filing Date: 2025-11-12
Form Type: 10-Q
Source: 0001790340-25-000135
Chunk: 407

Company: Immuneering Corp
Filing Date: 2025-11-12
Form: 10-Q
Item: Part I, Item 8
Chunk 407
---
) until the first anniversary of the closing date of the September 2025 Private Placement or such earlier time as the stand-still restrictions shall have fallen away, vote with respect to all voting securities of the Company as to which it is entitled to vote in accordance with the recommendation of a majority of the Company’s board of directors.The foregoing and other related summaries contained herein do not purport to be complete and are qualified in their entirety by reference to the September 2025 Purchase Agreement, which is filed as Exhibit 10.5 to this Quarterly Report on Form 10-Q.

20

Table of Contents

September 2025 Offering

On September 26, 2025, the Company completed the September 2025 Offering, pursuant to which it issued and sold 18,959,914 shares of its Class A common stock at an offering price of $9.23 per share, with Leerink Partners LLC and Oppenheimer & Co. Inc. acting as underwriters. The aggregate net proceeds received by the Company from the September 2025 Offering were $164.1 million, after deducting underwriting discounts and commissions, but before deducting offering costs payable by the Company, which were estimated to be approximately $0.4 million. 

Note 8 - Net Loss Per Share Attributable to Common Stockholders

Basic and diluted net loss per share attributable to common stockholders was calculated at September 30, 2025 and September 30, 2024 as follows:Three Months Ended September 30,Nine Months Ended September 30,2025202420252024Numerator:Net loss$(14,964,875)$(14,597,366)$(44,444,888)$(42,985,123)Denominator - basic and diluted:Weighted-average common shares outstanding, basic and diluted39,670,09529,841,88337,077,04129,622,670Net loss per share - basic and diluted$(0.38)$(0.49)$(1.20)$(1.45)The weighted average number of common shares used in the basic and diluted net loss per common share calculations includes the weighted-average pre-funded warrants outstanding during the period as they are exercisable at any time for nominal cash consideration. There were 1,077,764 Pre-Funded Warrants outstanding at September 30, 2025.The following table sets forth the potentially dilutive securities that have been excluded from the calculation of diluted net loss per share because to include them